Trial Profile
A Window of Opportunity Trial of Cetuximab in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Jul 2022 Status changed from active, no longer recruiting to completed.
- 13 Apr 2022 Planned End Date changed from 1 Mar 2023 to 1 Jul 2022.
- 13 Apr 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Jun 2022.